Phase ii study of vinorelbine in heavily previously treated small cell lung cancer

Oncology (Switzerland)

Volumn 53, Issue 2, 1996, Pages 169-172

  Furuse, Kiyoyuki ^a   Kubota, Kaoru ^a   Kawahara, Masaaki ^a   Takada, Minoru ^b   Kimura, Ikuro ^c   Fujii, Masafumi ^d   Ohta, Mitsuo ^e   Hasegawa, Kouichi ^f   Yoshida, Kiyokazu ^g   Nakajimah, Shigenori ^h   Ogura, Takeshi ⁱ   Niitani, Hisanobu ^j  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b City Hospital   (Italy)

^c UNIVERSITY OF BERN   (Switzerland)

^d EORTC DATA CENTER   (Belgium)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

^g SAITAMA CANCER CENTER   (Japan)

^h KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TOKUSHIMA   (Japan)

^j NIPPON MEDICAL SCHOOL   (Japan)

more..

Author keywords

Small cell lung cancer; Vinorelbine

Indexed keywords

NAVELBINE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE;

EID: 13344270908     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227555     Document Type: Article

References (18)

1. Manageney P, Andriamialiosa RZ, Langlios N, Langlois Y, Poiter P: A new class of antitumor compounds: 5'-norand 5',6'-scco derivatives of vinblastine-type alkaloids. J Org Chem 1979: 44:3765-3768.
2. Cross S, Wright M, Morimoto M, Lataste H, Couzinier JP, Krikorian A: Experimental antitumor activity of Navelbinc. Semin Oncol 1989; 16(supp14): 15-20.
3. Furuse K, Niitani H, Wakui AS, Hasegawa K, Furue H, Saito T, Tomonaga T, Majima H, Ohta K, Taguchi T, Fukuoka M, Nomura Y, Tsukagoshi S, Fujita H: Phase 1 study of vino-relbine (Navelbine) by single or intermittent administration (abstract). 6th N1C-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, 1989. p447.
4. Furuse K, Kubota K, Kawahara M, Kinuwaki E, Motomiya M, Nishiwaki Y, Niitani H, Saku-ma A: A phase II study of vinorelbine. a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 1994; 11:385-391.
5. Depierre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC; A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-119.
6. Fumolcau P, Delgado FM, Delozier T, Mon-nicr A, Delgado MAG, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L, Montcuquet P: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245-1252.
7. Conroy T, Etienne PL, Adenis A, Franqois E, Wagener DJT, Paillot B, Wils J, Delgada FM, Erie S, Van Pottelsbcrghc C, Bleibcrg H: Vinorelbine (Navelbine): A promising drug in metastatic epidermoid esophageal carcinoma (MEEC). Proc Am Soc Clin Oncol 1993; 12: 191.
8. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization. 1979. WHO Offset Publication No 8.
9. Aisner J: Identification of new drugs in small cell lunger cancer: Phase II agents first? Cancer Treat Rep 1987;71:1131-1133.
10. Cullen MH, Smith SR, Benfield GFA, Woo-droffe GM: Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: A phase II study of oral idarubicin in extensive disease. Cancer Treat Rep 1987:71:1227-1230.
11. Moore TD, Korn EL: Phase II trial design considerations for small-cell lung cancer. J Natl Cancer Inst 1992;84:150-154.
12. Grant SC, Gralla RJ, Kris MG, Orazem J, Kit-sis EA: Single-agent chemotherapy trials in small cell lung cancer, 1970 to 1990: The case for studies in previously treated patients. J Clin Oncol 1992;10:484-498.
13. Johnson DH: Investigation of new agents in small-cell lung cancer. Chest 1993; 103:423S-426S.
14. Cullen M: The design of phase II trials. Lung Cancer 1989:5:214-220.
15. Ettinger DS: Evaluation of new drugs in untreated patients with small cell lung cancer: Its time has come. J Clin Oncol 1990;8:374-377.
16. Giaccone G: Second line chemotherapy in small cell lung cancer. Lung Cancer 1989;5: 207-213.
17. Jassem H, Karnicka-Mlodkowska H, van Pot-telsberghe C, Glabbeke MV, Noseda MA, Ar-dizzoni A, Gozzclino F, Planting A. V an Zand-wijk N: Phase II study of vinorelbine Navel-binej in previously treated small cell lung cancer. EurJ Cancer 1993,29:1720-1722.
18. Furuse K, Niitani H, Sakuma A, Fukuoka M, Yamori S, Kuba M, Nakai II, Ncgoro S, Kata-gami N, Takada M, Kinuwaki E: Randomized comparative phase II study of vinorelbine (VRB) vs vindesinc (VDS) in previously untreated stage 1IIB or IV non-small cell lung cancer-Interim results. 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam. 1994. p 143.